-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QOsfF+yeuOWBYzZUeqWUGR2TWBYdxjdB4wDhMhvlDBi1GkUXqVGhlhtVZbOmTbh2 geOXz3C6QxJKyn8NDT9Dkg== 0000914760-02-000055.txt : 20020416 0000914760-02-000055.hdr.sgml : 20020416 ACCESSION NUMBER: 0000914760-02-000055 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20020410 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: TRIPOS INC CENTRAL INDEX KEY: 0000920691 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-PREPACKAGED SOFTWARE [7372] IRS NUMBER: 431454986 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-43843 FILM NUMBER: 02607314 BUSINESS ADDRESS: STREET 1: 1699 SOUTH HANLEY RD STREET 2: STE 303 CITY: ST LOUIS STATE: MO ZIP: 63144 BUSINESS PHONE: 3146471099 MAIL ADDRESS: STREET 1: 1699 SOUTH HANLEY RD STREET 2: STE 303 CITY: ST LOUIS STATE: MO ZIP: 63144 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: LION BIOSCIENCE AG CENTRAL INDEX KEY: 0001106774 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: WALDHOFER STRASSE 98 CITY: HEIDELBERG GERMANY STATE: I9 ZIP: D-69123 MAIL ADDRESS: STREET 1: WALDHOFER STRASSE 98 CITY: HEIDELBERG GERMANY ZIP: D-69123 SC 13D/A 1 l5390413da2.txt APRIL 10, 2002 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 -------------- SCHEDULE 13D Amendment No. 2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 TRIPOS, INC. - -------------------------------------------------------------------------------- (Name of Issuer) COMMON STOCK, PAR VALUE $.005 PER SHARE - -------------------------------------------------------------------------------- (Title of Class of Securities) 896928108 - -------------------------------------------------------------------------------- (CUSIP Number) with a copy to: Thomas Wirth, Esq. Bernard S. Kramer, Esq. LION bioscience Aktiengesellschaft McDermott, Will & Emery Im Neuenheimer Feld 515-517 227 West Monroe Street D-69123 Heidelberg, Germany Chicago, Illinois 60606 Tel. No.: 49 (6221) 4038-296 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) FEBRUARY 12, 2002 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this statement because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box: [ ] *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the act (however, see the Notes). SCHEDULE 13D CUSIP No. 896928108 - ------------------- - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON LION BIOSCIENCE AKTIENGESELLSCHAFT I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY) N/A - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS WC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [ ] - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION GERMANY - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF SHARES -0- BENEFICIALLY ____________________________________ OWNED BY EACH 8 SHARED VOTING POWER REPORTING PERSON -0- WITH ____________________________________ 9 SOLE DISPOSITIVE POWER -0- ------------------------------------ 10 SHARED DISPOSITIVE POWER -0- - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -0- - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ] - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON CO - -------------------------------------------------------------------------------- SCHEDULE 13D ITEM 1. SECURITY AND ISSUER This Amendment No. 2 to Schedule 13D relates to shares of common stock, par value $.005 per share (the "Common Stock") of Tripos, Inc., a Utah corporation ("Tripos" or the "Issuer"), having its principal executive offices at 1699 South Hanley Road, St. Louis, Missouri 63144, and amends the statement on Schedule 13G filed by the Reporting Person on February 16, 2000, as amended by Amendment No. 1 to Schedule 13D filed on February 12, 2001 (the "Prior Amendment"). ITEM 2. IDENTITY AND BACKGROUND (a), (b) & (c) This Amendment No. 2 to Schedule 13D is filed by LION bioscience AG, a German stock corporation duly incorporated under German law and registered in the commercial register Heidelberg under HRB 5706 ("LION" and the "Reporting Person"), whose business address is Im Neuenheimer Feld 515-517, D-69123 Heidelberg, Germany. LION is engaged in the business of enterprise-wide R&D data analysis and information management systems and solutions for the life sciences and, particularly, the healthcare industry. The overall integration system is i-biology. i-biology solutions are offered to partners and form the basis for LION's internal IT-driven drug discovery efforts on nuclear receptors. (d) & (e) Schedule A to the Prior Amendment contains a list of the members of the supervisory and management boards of LION and the following information with respect to each such person: (i) name; (ii) business address; (iii) present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted; and (iv) citizenship. During the last five years, LION and, to the best knowledge of LION, none of the persons named on Schedule A to the Prior Amendment has (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors); or (ii) has been a party to a civil proceeding of a judicial or administrative body resulting in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violations with respect to such laws. (f) LION is a German stock corporation. ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION See the information set forth under "Item 4. Purpose of Transaction," which is incorporated by reference in response to this Item 3. ITEM 4. PURPOSE OF TRANSACTION On February 12, 2002, LION sold its entire interest in Tripos in a private transaction for $26.444 per share. As a result of this sale LION ceased to be a beneficial owner of Tripos. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER (a) As of the date hereof, LION beneficial owns 0 of the outstanding shares of Common Stock of Tripos. Such shares represent in the aggregate approximately 0% of the outstanding shares of Common Stock of Tripos. (b) As a result of the sale described in Item 4 above, LION has no sole or shared power to vote any shares of Tripos. (c) Except as described in Item 4 above, LION has not effected any transaction in the Common Stock of Tripos since the Prior Filing. (d) No other person is known to LION to have the right to receive or the power to direct dividends from, or proceeds from the sale of, the Common Stock of Tripos. (e) February 12, 2002. ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER See the information set forth under "Item 4. Purpose of Transaction," which is incorporated by reference in response to this Item 6. ITEM 7. MATERIAL TO BE FILED AS EXHIBITS None. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 18, 2002 LION BIOSCIENCE AKTIENGESELLSCHAFT By: /s/ Friedrich von Bohlen ----------------------------------------- Name: Friedrich von Bohlen Title: Chairman and Chief Executive Officer -----END PRIVACY-ENHANCED MESSAGE-----